Glenmark Pharmaceuticals Receives ANDA Approval for Clobetasol Propionate Foam

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05 percent, a generic version of Olux Foam, 0.05 percent, of Mylan Pharmaceuticals, Inc. According to IQVIATM sales data for the 12-month period ending December 2018, the Olux Foam, 0.05 percent market achieved annual sales of approximately USD 50.9 million. Glenmark’s current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. – Medical Buyer Bureau